npj Vaccines (Jan 2022)
Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets
- In-Jeong Kim,
- Paula A. Lanthier,
- Madeline J. Clark,
- Rafael A. De La Barrera,
- Michael P. Tighe,
- Frank M. Szaba,
- Kelsey L. Travis,
- Timothy C. Low-Beer,
- Tres S. Cookenham,
- Kathleen G. Lanzer,
- Derek T. Bernacki,
- Lawrence L. Johnson,
- Amanda A. Schneck,
- Corinna N. Ross,
- Suzette D. Tardif,
- Donna Layne-Colon,
- Stephanie D. Mdaki,
- Edward J. Dick,
- Colin Chuba,
- Olga Gonzalez,
- Kathleen M. Brasky,
- John Dutton,
- Julienne N. Rutherford,
- Lark L. Coffey,
- Anil Singapuri,
- Claudia Sanchez San Martin,
- Charles Y. Chiu,
- Stephen J. Thomas,
- Kayvon Modjarrad,
- Jean L. Patterson,
- Marcia A. Blackman
Affiliations
- In-Jeong Kim
- Trudeau Institute, Inc.
- Paula A. Lanthier
- Trudeau Institute, Inc.
- Madeline J. Clark
- Trudeau Institute, Inc.
- Rafael A. De La Barrera
- Pilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research
- Michael P. Tighe
- Trudeau Institute, Inc.
- Frank M. Szaba
- Trudeau Institute, Inc.
- Kelsey L. Travis
- Trudeau Institute, Inc.
- Timothy C. Low-Beer
- Trudeau Institute, Inc.
- Tres S. Cookenham
- Trudeau Institute, Inc.
- Kathleen G. Lanzer
- Trudeau Institute, Inc.
- Derek T. Bernacki
- Trudeau Institute, Inc.
- Lawrence L. Johnson
- Trudeau Institute, Inc.
- Amanda A. Schneck
- Trudeau Institute, Inc.
- Corinna N. Ross
- Southwest National Primate Center, Texas Biomedical Research Institute
- Suzette D. Tardif
- Southwest National Primate Center, Texas Biomedical Research Institute
- Donna Layne-Colon
- Southwest National Primate Center, Texas Biomedical Research Institute
- Stephanie D. Mdaki
- Southwest National Primate Center, Texas Biomedical Research Institute
- Edward J. Dick
- Southwest National Primate Center, Texas Biomedical Research Institute
- Colin Chuba
- Southwest National Primate Center, Texas Biomedical Research Institute
- Olga Gonzalez
- Southwest National Primate Center, Texas Biomedical Research Institute
- Kathleen M. Brasky
- Southwest National Primate Center, Texas Biomedical Research Institute
- John Dutton
- Southwest National Primate Center, Texas Biomedical Research Institute
- Julienne N. Rutherford
- Department of Human Development Nursing Science, College of Nursing, University of Illinois Chicago
- Lark L. Coffey
- Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California
- Anil Singapuri
- Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California
- Claudia Sanchez San Martin
- Department of Laboratory Medicine, School of Medicine, University of California at San Francisco
- Charles Y. Chiu
- Department of Laboratory Medicine, School of Medicine, University of California at San Francisco
- Stephen J. Thomas
- Division of Infectious Diseases, Institute for Global Health and Translational Sciences, State University of New York, Upstate Medical University
- Kayvon Modjarrad
- Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research
- Jean L. Patterson
- Southwest National Primate Center, Texas Biomedical Research Institute
- Marcia A. Blackman
- Trudeau Institute, Inc.
- DOI
- https://doi.org/10.1038/s41541-021-00426-0
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 10
Abstract
Abstract Zika virus (ZIKV) is a mosquito-borne arbovirus that can cause severe congenital birth defects. The utmost goal of ZIKV vaccines is to prevent both maternal-fetal infection and congenital Zika syndrome. A Zika purified inactivated virus (ZPIV) was previously shown to be protective in non-pregnant mice and rhesus macaques. In this study, we further examined the efficacy of ZPIV against ZIKV infection during pregnancy in immunocompetent C57BL6 mice and common marmoset monkeys (Callithrix jacchus). We showed that, in C57BL/6 mice, ZPIV significantly reduced ZIKV-induced fetal malformations. Protection of fetuses was positively correlated with virus-neutralizing antibody levels. In marmosets, the vaccine prevented vertical transmission of ZIKV and elicited neutralizing antibodies that remained above a previously determined threshold of protection for up to 18 months. These proof-of-concept studies demonstrate ZPIV’s protective efficacy is both potent and durable and has the potential to prevent the harmful consequence of ZIKV infection during pregnancy.
